Exploratory, Randomized, Double-blind, Placebo-controlled Study on the Effects of Bifidobacterium infantis Natren Life Start Strain Super Strain in Active Celiac Disease
暂无分享,去创建一个
E. Smecuol | H. Vázquez | S. Niveloni | E. Mauriño | J. Bai | J. Meddings | H. Hwang | R. Mazure | E. Sugai | Andrea González | A. Cherñavsky | L. Corso | F. Vodánovich | G. Lozano | Franco P. Bellavite | M. L. Moreno
[1] A. Caminero,et al. Differences of small intestinal bacteria populations in adults and children with/without celiac disease: Effect of age, gluten diet, and disease , 2012, Inflammatory bowel diseases.
[2] C. Pert,et al. Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2- and CCR5-mediated monocyte chemotaxis and inflammation , 2012, PAIN.
[3] L. Laghi,et al. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization , 2011, BMC Microbiology.
[4] J. Ludvigsson,et al. Clinical management of coeliac disease , 2011, Journal of internal medicine.
[5] R. Ffrench,et al. A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2® in HLA DQ2+ Volunteers With Celiac Disease Following a Long-Term, Strict Gluten-Free Diet , 2011 .
[6] J. Fox,et al. TLR2-dependent pathway of heterologous down-modulation for the CC chemokine receptors 1, 2, and 5 in human blood monocytes. , 2011, Blood.
[7] E. Smecuol,et al. Long-term deterioration of quality of life in adult patients with celiac disease is associated with treatment noncompliance. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[8] E. Smecuol,et al. Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[9] Y. Sanz,et al. Pivotal Advance: Bifidobacteria and Gram‐negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease , 2010, Journal of leukocyte biology.
[10] E. Ricca,et al. Modulation of the immune response by probiotic strains in a mouse model of gluten sensitivity. , 2009, Cytokine.
[11] G. Rubin,et al. Systematic review: adherence to a gluten‐free diet in adult patients with coeliac disease , 2009, Alimentary pharmacology & therapeutics.
[12] J. Murray,et al. Between Celiac Disease and Irritable Bowel Syndrome: The “No Man's Land” of Gluten Sensitivity , 2009, The American Journal of Gastroenterology.
[13] James Versalovic,et al. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. , 2009, Gastroenterology.
[14] Y. Sanz,et al. Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease , 2008, BMC Microbiology.
[15] Y. Sanz,et al. Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients , 2008, Journal of Inflammation.
[16] K. Madsen,et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. , 2008, American journal of physiology. Gastrointestinal and liver physiology.
[17] K. Kaukinen,et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture , 2008, Clinical and experimental immunology.
[18] A. Fasano,et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT‐1001 in coeliac disease subjects: a proof of concept study , 2007, Alimentary pharmacology & therapeutics.
[19] Andrew G. Spencer,et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. , 2007, Gastroenterology.
[20] P. Whorwell,et al. Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome , 2006, The American Journal of Gastroenterology.
[21] U. Chattopadhyay,et al. Macrophage inflammatory protein (MIP)1α and MIP1β differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy , 2006, Cancer Immunology, Immunotherapy.
[22] M. Gobbetti,et al. Proteolytic activity and reduction of gliadin‐like fractions by sourdough lactobacilli , 2005, Journal of applied microbiology.
[23] A. Zinsmeister,et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating , 2005, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[24] M. Bauserman,et al. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. , 2005, The Journal of pediatrics.
[25] D. Schuppan,et al. Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management. , 2005, Nutrition in clinical care : an official publication of Tufts University.
[26] S. James. National Institutes of Health Consensus Development Conference Statement on Celiac Disease, June 28-30, 2004. , 2005, Gastroenterology.
[27] F. Shanahan,et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. , 2005, Gastroenterology.
[28] W. Karpus,et al. CCR5 Regulates High Dose Oral Tolerance by Modulating CC Chemokine Ligand 2 Levels in the GALT1 , 2004, The Journal of Immunology.
[29] L. Greco,et al. Sourdough Bread Made from Wheat and Nontoxic Flours and Started with Selected Lactobacilli Is Tolerated in Celiac Sprue Patients , 2004, Applied and Environmental Microbiology.
[30] R. Di Cagno,et al. Proteolysis by Sourdough Lactic Acid Bacteria: Effects on Wheat Flour Protein Fractions and Gliadin Peptides Involved in Human Cereal Intolerance , 2002, Applied and Environmental Microbiology.
[31] A. Fasano,et al. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. , 2001, Gastroenterology.
[32] M. Horton,et al. Distinct Requirements for C-C Chemokine and IL-2 Production by Naive, Previously Activated, and Anergic T Cells , 2000, The Journal of Immunology.
[33] D. Goeddel,et al. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes , 1993, The Journal of experimental medicine.
[34] Govind Bhagat,et al. Serum cytokine elevations in celiac disease: association with disease presentation. , 2010, Human immunology.
[35] J. Laparra,et al. Bifidobacteria inhibit the inflammatory response induced by gliadins in intestinal epithelial cells via modifications of toxic peptide generation during digestion , 2010, Journal of cellular biochemistry.
[36] V. Gonzalez,et al. Quality of life in celiac disease patients: prospective analysis on the importance of clinical severity at diagnosis and the impact of treatment. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[37] A. Fasano,et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. , 2007, The American journal of clinical nutrition.
[38] T. Schall,et al. Human Macrophage Inflammatory Protein cr ( MIP-lc ~ ) and MIPI ~ Chemoklnes Attract Distinct Populations of Lymphocytes , 2003 .
[39] B. V. von Blomberg,et al. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice , 1999, American Journal of Gastroenterology.